Interpreting HER2 IHC results is a critical step in the molecular diagnostics of breast cancer, directly influencing treatment eligibility. The assessment requires pathologists to evaluate the intensity and completeness of cell membrane staining in invasive carcinoma cells. This semi-quantitative scoring system provides essential information regarding targeted therapy options, making accuracy paramount.
Understanding the HER2 Protein in Oncogenesis
HER2, or human epidermal growth factor receptor 2, is a transmembrane glycoprotein involved in normal cellular growth and differentiation. When amplified or overexpressed, it leads to uncontrolled signaling that promotes aggressive tumor behavior. The IHC assay serves as the primary screening tool to detect this protein's presence on the cell surface, acting as a vital bridge between pathology and precision oncology.
Technical Protocol and Tissue Handling
Standardization begins with optimal tissue fixation using neutral buffered formalin for no more than 48 hours before processing. Prolonged fixation can mask epitopes, leading to false-negative results. The tissue is then embedded in paraffin, sectioned, and mounted on charged slides to ensure adequate adhesion during the staining procedure.
Key Steps in the IHC Procedure
Deparaffinization and rehydration of the tissue section.
Antigen retrieval using high-temperature citrate buffer to expose binding sites.
Application of primary antibodies specific to the HER2 peptide.
Enzymatic or polymer-based detection systems amplifying the signal.
chromogenic visualization using substrates like DAB for brown coloration.
The Scoring Criteria Explained
The ASCO/CAP guidelines provide a standardized framework for reporting, categorizing results into scores of 0, 1+, 2+, and 3+. Each score corresponds to specific patterns of membrane staining intensity and completeness. This classification minimizes subjectivity and ensures reproducibility across different laboratories.
Score | Intensity | Completeness | Clinical Action
0 | Negative or faint incomplete | <10% of cells | HER2 negative; anti-HER2 therapy not indicated
1+ | Weak incomplete | <30% of cells | HER2 negative; anti-HER2 therapy not indicated
2+ | Weak to moderate complete | >10% of cells | Equivocal; reflex ISH/FISH required
3+ | Strong complete | >70% of cells | HER2 positive; anti-HER2 therapy recommended
Common Pitfalls and Artifacts
Pathologists must recognize artifacts that can mimic true positivity. Cytoplasmic staining, while common, should never be scored. Necrotic tissue and crush artifacts often create假象 of strong positivity. Furthermore, edge artifacts due to incomplete tissue processing can lead to misinterpretation, requiring careful microscopic evaluation of the entire section.
Quality Control and External Proficiency
Laboratories must participate in external quality assessment programs to validate their HER2 IHC performance. Internal controls, including positive and negative tissue controls, ensure the integrity of each staining run. Continuous calibration of reagents and maintenance of instrumentation are non-negotiable requirements for reliable diagnostics.
